Maybe a New Target for Gliomas: AQP1

Gliomas are the most common and aggressive tumors of the central nervous system. However, the prognosis of gliomas is poor. Therefore, studies that will form the basis for the diagnosis and treatment of the disease are very important for these patient groups. In this study, members of the Aquaporin family in gliomas were examined, and the relationships of AQP1 and AQP4 with gliomas were investigated. In this study conducted using in silico methods, the expression levels of the AQP family in LGG and GBM-type gliomas were compared. As a result of the findings, the prognostic value and clinical importance of AQP1 and AQP4 were evaluated by using GEPIA, UCSC Xena, Gliovis, cBioPortal, and Ivy GAP analysis tools. According to the data, AQP1 and AQP4 gene expressions were found as more expressed in tumor tissue than in normal tissue in the LGG and GBM datasets. The effects of these two genes on the survival and prognosis of patients were investigated using the expression patterns in the LGG and GBM datasets. When compared the expression levels of these two genes in the subtypes, AQP1 was found low in the Oligodendrogram subtype of LGG, and both AQP1 and AQP4 levels were high in all the remaining subtypes. With these findings, both AQP4 and AQP1 from the aquaporin family are effective genes in the pathogenesis of gliomas and patient survival. AQP1 may be used as a new drug target or biomarker against aggressive gliomas. Therefore, it should be evaluated for future studies.